Horizon Therapeutics PLC
NASDAQ:HZNP
Horizon Therapeutics PLC
Cash from Financing Activities
Horizon Therapeutics PLC
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Horizon Therapeutics PLC
NASDAQ:HZNP
|
Cash from Financing Activities
-$334.4m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
Alkermes Plc
NASDAQ:ALKS
|
Cash from Financing Activities
-$289.7m
|
CAGR 3-Years
-409%
|
CAGR 5-Years
-183%
|
CAGR 10-Years
N/A
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Cash from Financing Activities
$230k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-74%
|
CAGR 10-Years
-47%
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Cash from Financing Activities
$45.1m
|
CAGR 3-Years
490%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-6%
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Cash from Financing Activities
$468.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Horizon Therapeutics PLC's Cash from Financing Activities?
Cash from Financing Activities
-334.4m
USD
Based on the financial report for Jun 30, 2023, Horizon Therapeutics PLC's Cash from Financing Activities amounts to -334.4m USD.
What is Horizon Therapeutics PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-49%
Over the last year, the Cash from Financing Activities growth was -267%. The average annual Cash from Financing Activities growth rates for Horizon Therapeutics PLC have been -68% over the past three years , -49% over the past five years .